NOI SS 1229151.pdf

75F40120Q00127

Notice of Intent to Sole Source for a PromethION

The Food and Drug Administration (FDA), the Office of Acquisitions and Grants Services (OAGS) intends to inform the public that the FDA anticipates issuing an award to purchase a PromethION 24 compact benchtop system designed to run and analyze up to 24 PromethION Flow Cells (PR02) — delivering yields of up to 4,800 Gbases. The Period of Performance includes a one-year Base Period and three (1) year option years.

In accordance with FAR part 6.302-1, Oxford Nanopore Technologies Inc. is the only known responsible source who can provide the required services as no other source has been identified who can provide the requirements listed below.

The FDA intends to award a purchase order to Oxford Nanopore Technologies Inc. located at One Kendall Square, Building 1400 Suite 14-305, Cambridge, MA, 02139.

This notice is not a request for competitive quotes. However, any party that believes it is capable of meeting the requirements as stated herein may submit a written capability statement that clearly supports and demonstrates their ability to perform the requirement. A determination by the Government to compete this proposed award based upon responses to this notice is solely within the discretion of the Government.

It is anticipated that an award will be issued within approximately five (5) days after the date of this notice unless the Government determines that any other organization has the capability to meet this requirement.

Please email responses to Janae Hughes at janae.hughes@fda.hhs.gov. No phone calls will be accepted.

mailto:janae.hughes@fda.hhs.gov